SCPS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCPS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Scopus BioPharma's change in inventory for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Scopus BioPharma's inventory stayed the same from Mar. 2023 to Jun. 2023 .
Scopus BioPharma's change in inventory for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Scopus BioPharma's inventory stayed the same from Dec. 2021 to Dec. 2022 .
Scopus BioPharma's Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Scopus BioPharma's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scopus BioPharma Annual Data | |||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Scopus BioPharma Quarterly Data | ||||||||||||||||||||
Jun18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scopus BioPharma (OTCPK:SCPS) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Scopus BioPharma's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Scopus BioPharma's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Scopus BioPharma's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Scopus BioPharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Ira Scott Greenspan | director | 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106 |
Joshua R Lamstein | director, officer: Chairman | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Alan M Horsager | officer: See Remarks | 1021 N EVERETT STREET, GLENDALE CA 91207 |
Robert J Gibson | director, officer: Vice Chairman | 71 LANTERN RIDGE RD, NEW CANAAN CT 06840 |
Lesley Russell | director | 41 MOORES RD., FRAZER PA 19355 |
Iv David Weild | director | 22 ORIOLE AVENUE, BRONXVILLE NY 10708 |
David S. Battleman | director | C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019 |
David A. Buckel | director | SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601 |
Raphael Hofstein | director | C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120 |
Paul Hopper | director | 7982 DOUG HILL, SAN DIEGO CA 92127 |
Ashish P Sanghrajka | director, officer: President | 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 03-23-2022
By PRNewswire PRNewswire • 01-06-2022
By GuruFocusNews GuruFocusNews • 12-17-2021
By GlobeNewswire GlobeNewswire • 10-08-2021
By GuruFocusNews GuruFocusNews • 03-23-2022
By Marketwired Marketwired • 09-29-2021
By Marketwired Marketwired • 09-07-2021
By Marketwired Marketwired • 09-28-2021
By Marketwired Marketwired • 10-08-2021
By Marketwired Marketwired • 09-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.